On February 23, Ge Longhui (688276.SH) announced the 2023 Annual Results Report. During the reporting period, the company's total operating revenue was 1,825 million yuan, up 70.30% year on year; net profit attributable to parent company owners was 501 million yuan, up 175.98% year on year; net profit attributable to parent company owners after deducting non-recurring profit and loss was 493 million yuan, up 195.86% year on year.
Affected by factors such as the decline in the birth rate of domestic newborns, domestic sales of the live attenuated chickenpox vaccine declined, and export sales increased; sales of the live attenuated vaccine from freeze-dried nasal spray were basically the same as the previous year; the company obtained the “Drug Registration Certificate” for the live attenuated herpes zoster vaccine in early 2023, obtained the “Biological Product Batch Issuance Certificate” in April 2023, and achieved sales one after another, enriching the company's overall revenue scale and net profit.